ArticleHereditary cancer in clinical practice2026
Importance of genetic testing in childhood cancer survivors for hereditary cancer predisposition syndromes.
Article in Hereditary cancer in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAround 10% of children with cancer carry a germline pathogenic or likely pathogenic variant (P/LPV) in one of the cancer predisposition genes. The objective of this study was to evaluate the frequency of genetic testing for hereditary cancer predisposition syndromes (HCPSs) among adults treated for childhood cancer in Slovenia and to characterize the P/LPVs identified in those who opted for genetic testing. We also aimed to analyse how a positive genetic test influences cascade testing in blood relatives.
methodsWe included patients born between 1970 and 2000 who were diagnosed and treated for cancer between ages 0 − 18 into this retrospective, descriptive, cross-sectional study. Data were collected from the Cancer Registry of the Republic of Slovenia, Long-term Follow-Up Clinic (LTFUC) and the Department of Clinical Cancer Genetics (DCCG) databases. The proportion of tested individuals was calculated with a 95% confidence interval (CI) using the Wald’s method.
resultsOf 1,475patients diagnosed and treated for cancer in childhood, 59 (4.0%; 95% CI: 3.0–5.0%) underwent genetic testing, with 35.6% (21/59) testing positive. The P/LPV were most frequently found in RB1, NF1, RET and BRCA2 genes. In 61.9% (13/21) of positive cases, an identified cancer predisposition syndrome was linked to the childhood cancer; in 95.2% (20/21) it conferred an increased adult cancer risk. Among six patients with P/LPV and second primary cancer (SPC), two had SPC with possible association with the HCPS. Cascade genetic testing was performed in 38.1% (8/21) of positive families and was documented for 35 relatives of 8 carriers of P/LPV. Overall, 60% (21/35) of relatives were positive at genetic testing and 47.6% (10/21) of developed cancer. In 90% (9/10) of relatives the cancer could be linked to the HCPS.
conclusionsOnly 4% of childhood cancer survivors underwent genetic testing for HCPS. Since hereditary cancer predisposition identified in childhood may also increase cancer risk in adulthood, universal cancer genetic counselling and testing should be considered in childhood to timely enable preventive options for early cancer detection and risk reduction procedures in carriers of P/LPV. In parallel, cascade genetic testing among blood relatives may also offer preventive opportunities to those at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.